WALTHAM, MA, October 9, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has enrolled the first patient in its follow-on pilot study for punctate epitheliopathies (“PE”). The study will use the Ocular Bandage Gel…
WALTHAM, MA, April 01, 2021 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing products for treating inflammatory and immune diseases, today announced that it has appointed Kenneth Gayron and Aron Shapiro to the Company’s Board of Directors, effective immediately. Thomas Hancock, Morton Goldberg, M.D., and Bernard Malfroy-Camine, Ph.D., have…
WALTHAM, MA, December 21, 2020 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical stage company focused on developing products for treating disorders of the eye, today announced the acquisition of Panoptes Pharma (“Panoptes”), a privately-held clinical stage biotech company focused on developing a novel proprietary small molecule for the treatment…
Patent Further Strengthens EyeGate’s Global IP Protection for Lead Product Candidate, EGP-437 WALTHAM, Mass., January 23, 2017 — Eyegate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced that it has been granted…
WALTHAM, MA, January 6, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has completed enrollment in its follow-on pilot study for punctate epitheliopathies (“PE”) with a focus on patients with dry eye. The study…
WALTHAM, MA, October 9, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has completed randomization for its corneal wound repair pivotal study using the Ocular Bandage Gel (“OBG”) eye drop. The study enrolled a…
Proof-of-concept study conducted in Austria; Study designed to build upon positive Phase 1 safety data in healthy volunteers -Trial remains on track with topline data expected in Q4 2021- WALTHAM, MA, September 8, 2021 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company developing and commercializing products for treating…
WALTHAM, Mass., July 31, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has completed randomization of over 25% of the patients required for its corneal wound repair pivotal study using the Ocular Bandage Gel…
WALTHAM, MA, August 29, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced today a reverse stock split of its shares of common stock at a ratio of 1-for-15. Upon the commencement of trading on August 30, 2019,…
WALTHAM, MA, December 2, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has received additional positive topline data in its corneal wound repair pivotal study. As previously announced, the results of this pivotal study…